BioSpace News Archive

Mallinckrodt plc, a global biopharmaceutical company, announced the publication of findings from a retrospective medical records study assessing the real-world utilization and outcomes of Acthar® Gel in patients with refractory rheumatoid arthritis that did not adequately respond to standard-of-care therapies.

Atea Pharmaceuticals, Inc. today presented two posters highlighting nonclinical data demonstrating the nonclinical safety of bemnifosbuvir (AT-527) at the Society of Toxicology (SOT) 61st Annual Meeting taking place in San Diego, California from March 27 – 31, 2022.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2021, and provided business highlights.

Cara Therapeutics, Inc. (Nasdaq: CARA), today announced data from a sub-study of the KARE Phase 2 clinical trial demonstrated Oral KORSUVA™ (difelikefalin) improved itch and inflammatory biomarkers in atopic dermatitis (AD) patients with moderate-to-severe pruritus.

Immunovant, Inc. today announced that it will host a virtual R&D event on Wednesday, March 30, 2022, from 9:00 AM ET to 11:00 AM ET.

Amarin Corporation plc announces that the Company received its first national reimbursement in a European country for VAZKEPA® in Sweden and provides an update on the status of its international expansion strategy, including several regulatory filing and reimbursement updates for VASCEPA®/VAZKEPA globally.

Anavex Life Sciences Corp. announced that Anavex Management team will participate in the Rare Neurodevelopmental Disorders Panel at the Cantor Virtual Rare Disease Summit on Wednesday, March 30, 2022 at 11:00 AM ET.

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its fourth quarter and full year ended December 31, 2021.

ASLAN Pharmaceuticals today announced the oral presentation of data from the completed Phase 1b multiple-ascending-dose (MAD) study that established proof of concept for eblasakimab.

The global market for surgical instrument tracking systems is poised for double-digit growth rate in the near future.